PLK1 and non-small cell lung carcinoma: However, the cell line that we chose as the representative of SMARCA4 mutant NSCLCs, NCI-H1819, has a slow growth rate with an average doubling time of 53 h, which is higher than the mean doubling time of the NSCLC lines harbouring wild-type SMARCA4. We also used siRNAs against the mitotic kinase PLK1, and antimitotic drugs Paclitaxel and GSK923295 as controls, to detect possible cell doubling rate-related effects.